Consolidated Balance Sheets - USD ($)	Dec. 31, 2021	Dec. 31, 2020
Current assets:
Cash and cash equivalents	$ 8,589,000	$ 10,596,000
Accounts receivable		157,000
Prepaid expenses and other current assets	816,000	533,000
Total current assets	9,405,000	11,286,000
Property and equipment, net	297,000	416,000
Operating lease right-of-use asset	141,000
TOTAL ASSETS	9,843,000	11,702,000
Current liabilities:
Accounts payable	1,061,000	3,169,000
Accrued expenses	980,000	1,937,000
Senior secured convertible debt, net		8,074,000
Current portion of long-term debt	74,000
Operating lease right-of-use liability	140,561
Total current liabilities	2,256,000	13,180,000
Long-term debt	175,000	1,134,000
TOTAL LIABILITIES	2,431,000	14,314,000
Commitments and contingencies (Note 7)
Stockholders’ equity (deficit):
Common stock, par value of $0.0001 per share; 100,000,000 shares authorized as of December 31, 2021, and December 31, 2020; 30,801,962 and 22,388,027 shares issued as of December 31, 2021 and December 31, 2020, respectively; 30,801,110 and 22,387,175 shares outstanding as of December 31, 2021 and December 31, 2020, respectively	3,000	3,000
Additional paid-in capital	307,281,000	250,914,000
Treasury stock, at cost; 852 shares of common stock as of December 31, 2021 and December 31, 2020, respectively	(11,000)	(11,000)
Accumulated deficit	(299,861,000)	(277,481,000)
Total Vaccinex, Inc. stockholders’ equity (deficit)	7,412,000	(26,575,000)
Noncontrolling interests		23,963,000
TOTAL STOCKHOLDERS’ EQUITY (DEFICIT)	7,412,000	(2,612,000)
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY	$ 9,843,000	$ 11,702,000